BMI and TLC Influences Doxorubicin/Epirubicin Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer
| Main Authors: | Priyono, Sasongko Hadi, Putra, Oscar Tri Joko, Yasmina, Alfi, Poerwosusanta, Hery, Rahman, Eka Yudha, Oktaviyanti, Ika Kustiyah |
|---|---|
| Format: | Article info application/pdf eJournal |
| Bahasa: | eng |
| Terbitan: |
Faculty of Medicine, Universitas Padjadjaran
, 2022
|
| Subjects: | |
| Online Access: |
https://journal.fk.unpad.ac.id/index.php/mkb/article/view/2797 https://journal.fk.unpad.ac.id/index.php/mkb/article/view/2797/pdf https://journal.fk.unpad.ac.id/index.php/mkb/article/downloadSuppFile/2797/3372 |
Daftar Isi:
- Anthracycline-based neoadjuvant chemotherapy is the recommended therapy for locally advanced breast cancer (LABC) patients. Unfortunately, no study has reported the relationship between body mass index (BMI), total lymphocyte count (TLC), and responses to this type of chemotherapy. This study aimed to determine the relationship between BMI, TLC, and response to doxorubicin/epirubicin neoadjuvant chemotherapy in LABC patients. A retrospective cohort design was applied to medical records of LABC patients undergoing neoadjuvant chemotherapy at Ulin General Hospital Banjarmasin, Indonesia, from July to December 2021. BMI and TLC data were assessed based on the values before chemotherapy, while the chemotherapy response was measured using the RECIST 1.1 criteria after 3 cycles. Multinomial logistic regression test with 95% confidence level was used to analyze these data. The results showed that as many as 71% of patients experienced a Partial Response (PR), while 5% and 23% of the patients demonstrated Stable Disease (SD) and Progressive Disease (PD), respectively. Each increase in BMI of 1 kg/m2 was significantly associated with an increase in the occurrence of PR and PD by 1.26 times and 1.29 times, respectively, when compared to the occurrence of PD. Meanwhile, an increase in TLC of 100 cells/mm3 was associated with an increase in the occurrence of PR by 6.83 times and an increase in the occurrence of SD. of 6.94 when compared to the occurrence of PD. Therefore, there is a significant relationship between BMI, TLC, and response to anthracycline-based neoadjuvant chemotherapy in LABC patients
- Neoadjuvant chemotherapy, especially anthracycline based, is the recommended therapy for Locally Advanced Breast Cancer (LABC). There has been no study reported the relationship between Body Mass Index (BMI) and Total Lymphocyte Count (TLC) with neoadjuvant chemotherapy response in patients with LABC. The purpose of this study is to determine the relationship between BMI and TLC with the response to anthracycline-based neoadjuvant chemotherapy in LABC patients. This study applies a retrospective cohort design. Each increase in BMI of 1 kg/m2 is significantly associated with an increase in the occurrence of PR by 1.26 times compared to the occurrence of PD (aRR 1.26, 95%CI 1.085-1.458, p = 0.002), and every increase in BMI of 1 kg/m2 is significantly associated with an increase in the occurrence of SD by 1.29 times compared to the occurrence of PD (aRR 1.29, 95%CI 1.034-1.615, p = 0.024). Meanwhile, an increase in TLC of 100 cells/mm3 with an increase in the occurrence of PR by 6.83 times compared to the occurrence of PD (aRR 6.83, 95%CI 2.213-21.063, p = 0.001), and an increase in TLC of 100 cells/m3is significantly associated with an increase in the occurrence of SD. of 6.94 compared to the occurrence of PD (aRR 6.9 4, 95%CI 1.419-33.929, p = 0.017). It can be concluded that there is a significant relationship between BMI and TLC with the response to anthracycline-based neoadjuvant chemotherapy in LABC patients.